Literature DB >> 18707696

Outcomes following active surveillance of men with localized prostate cancer diagnosed in the prostate specific antigen era.

Barbara Ercole1, Sarah R Marietti, Judith Fine, Peter C Albertsen.   

Abstract

PURPOSE: We gained insights concerning outcomes associated with men who elect active surveillance for the management of localized prostate cancer.
MATERIALS AND METHODS: This is a retrospective case series analysis of 40 patients diagnosed with localized prostate cancer since 1990 who elected active surveillance.
RESULTS: A total of 31 patients remained on active surveillance for a median of 48 months (range 12 to 168). The 5-year probability of remaining on active surveillance was 74%. Most patients who abandoned this strategy did so within 33 months of diagnosis (range 12 to 84). An increasing prostate specific antigen and anxiety were the 2 most common reasons. A delay in treatment did not appear to compromise subsequent outcomes.
CONCLUSIONS: Men with low grade prostate cancer can elect active surveillance and have excellent long-term results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18707696     DOI: 10.1016/j.juro.2008.06.027

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  14 in total

1.  [Active surveillance of low risk prostate cancer].

Authors:  K Lellig; B Beyer; M Graefen; D Zaak; C Stief
Journal:  Urologe A       Date:  2014-07       Impact factor: 0.639

2.  Quality of life in men undergoing active surveillance for localized prostate cancer.

Authors:  Jonathan Bergman; Mark S Litwin
Journal:  J Natl Cancer Inst Monogr       Date:  2012-12

3.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

Authors:  Baris Turkbey; Vijay P Shah; Yuxi Pang; Marcelino Bernardo; Sheng Xu; Jochen Kruecker; Julia Locklin; Angelo A Baccala; Ardeshir R Rastinehad; Maria J Merino; Joanna H Shih; Bradford J Wood; Peter A Pinto; Peter L Choyke
Journal:  Radiology       Date:  2010-12-21       Impact factor: 11.105

4.  Impact of race on survival in patients with clinically nonmetastatic prostate cancer who deferred primary treatment.

Authors:  Michael Koscuiszka; David Hatcher; Paul J Christos; Amy E Rose; Holly S Greenwald; Ya-lin Chiu; Samir S Taneja; Madhu Mazumdar; Peng Lee; Iman Osman
Journal:  Cancer       Date:  2011-10-21       Impact factor: 6.860

5.  Polymorphisms in glutathione S-transferase genes increase risk of prostate cancer biochemical recurrence differentially by ethnicity and disease severity.

Authors:  Nora L Nock; Cathryn Bock; Christine Neslund-Dudas; Jennifer Beebe-Dimmer; Andrew Rundle; Deliang Tang; Michelle Jankowski; Benjamin A Rybicki
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

6.  Active surveillance for the management of localized prostate cancer: Guideline recommendations.

Authors:  Chris Morash; Rovena Tey; Chika Agbassi; Laurence Klotz; Tom McGowan; John Srigley; Andrew Evans
Journal:  Can Urol Assoc J       Date:  2015 May-Jun       Impact factor: 1.862

Review 7.  Defining and Measuring Adherence in Observational Studies Assessing Outcomes of Real-world Active Surveillance for Prostate Cancer: A Systematic Review.

Authors:  Glenda Kith; Sarah Lisker; Urmimala Sarkar; Jill Barr-Walker; Benjamin N Breyer; Nynikka R Palmer
Journal:  Eur Urol Oncol       Date:  2019-07-06

8.  Update on the management of prostate cancer with goserelin acetate: patient perspectives.

Authors:  Shandra Wilson
Journal:  Cancer Manag Res       Date:  2009-08-12       Impact factor: 3.989

9.  An update on the changing indications for androgen deprivation therapy for prostate cancer.

Authors:  Kristene Myklak; Shandra Wilson
Journal:  Prostate Cancer       Date:  2011-02-07

10.  Should active surveillance in prostate cancer patients be based on a single histological assessment?

Authors:  Lukasz Nyk; Tomasz Golabek; Jakub Dobruch; Michał Andrzej Skrzypczyk; Tomasz Dzik; Maciej Wysocki; Piotr L Chłosta; Andrzej Borówka
Journal:  Cent European J Urol       Date:  2014-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.